A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Exclusion Criteria

• •Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc
• •For HCC lesions ≥ 10 cm in any dimension, imaging evaluation showed that there were more than 10 lesions
• •The main portal vein and the left and right primary branches were clogged with cancer thrombus
• •History of hepatic encephalopathy or liver transplantation
• •Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.
• •Occurred arteriovenous thromboembolic events within 6 months before the first administration.
• •Inadequately controlled hypertension.
• •Attack of symptomatic congestive heart failure (LVEF\<50%); History of congenital long QT syndrome.
• •Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease.
• •Severe infections.
• •Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,
• •Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs.
• •Unable to receive an enhanced CT or MRI scan of the liver.